ABSTRACT
The authors summarized the evidence supporting neuroprotection based on the data available in the literature. In vivo and in vitro studies have indicated that many compounds can decrease neurodegeneration, excitotoxicity, oxidative stress, protein aggregation, disturbance of Ca2+ homeostasis and compensate the energy impairment. Selegiline, rasagiline, dopamine agonists and other molecules (ubiquinone, kynurenic acid, tocopherol, creatine, glatiramer acetate) exert neuroprotective effects in preclinical studies. Much less clinical data are available regarding neuroprotection in different neurological disorders. In this review, such preclinical and clinical evidences are summarized.
Subject(s)
Nerve Degeneration/drug therapy , Neurodegenerative Diseases/drug therapy , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Animals , Creatine/pharmacology , Creatine/therapeutic use , Dopamine Agonists/pharmacology , Dopamine Agonists/therapeutic use , Glatiramer Acetate , Humans , Indans/pharmacology , Indans/therapeutic use , Kynurenic Acid/pharmacology , Kynurenic Acid/therapeutic use , Micronutrients/pharmacology , Micronutrients/therapeutic use , Oxidative Stress/drug effects , Peptides/pharmacology , Peptides/therapeutic use , Selegiline/pharmacology , Selegiline/therapeutic use , Tocopherols/pharmacology , Tocopherols/therapeutic use , Ubiquinone/pharmacology , Ubiquinone/therapeutic useABSTRACT
In this paper the authors review the relationship and the possible interaction between the HMG-CoA reductase inhibitors (statins) and the CoQ10 (ubiquinone) based on the current literature. The statins are widely used in the clinical practice. Inhibiting the synthesis of mevalonic acid they decrease the plasma cholesterol level. Since mevalonic acid is also required for ubiquinone synthesis statins could influence ubiquinone metabolism. Many studies confirmed the relationship between statin therapy and lower plasma ubiquinone level. Much less data are available about the tissue concentration changes of ubiquinone during statin therapy. The authors try to summarise the consequences of the interaction between statin therapy and ubiquinone metabolism.